Limits...
Enhancement of anti-murine colon cancer immunity by fusion of a SARS fragment to a low-immunogenic carcinoembryonic antigen.

Lin CS, Kao SH, Chen YC, Li CH, Hsieh YT, Yang SC, Wu CJ, Lee RP, Liao KW - Biol Proced Online (2012)

Bottom Line: It is widely understood that tumor cells express tumor-associated antigens (TAAs), of which many are usually in low immunogenicity; for example, carcinoembryonic antigen (CEA) is specifically expressed on human colon cancer cells and is viewed as a low-immunogenic TAA.How to activate host immunity against specific TAAs and to suppress tumor growth therefore becomes important in cancer therapy development.Oral vaccination of an attenuated Salmonella typhimurium strain transformed with plasmids encoding CEA-SARS-CoV fusion gene into BALB/c mice elicited significant increases in TNF-α and IL-10 in the serum.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Biological Science and Technology, National Chiao-Tung University, Hsin-Chu, Taiwan. liaonms@pchome.com.tw.

ABSTRACT

Background: It is widely understood that tumor cells express tumor-associated antigens (TAAs), of which many are usually in low immunogenicity; for example, carcinoembryonic antigen (CEA) is specifically expressed on human colon cancer cells and is viewed as a low-immunogenic TAA. How to activate host immunity against specific TAAs and to suppress tumor growth therefore becomes important in cancer therapy development.

Results: To enhance the immune efficiency of CEA in mice that received, we fused a partial CEA gene with exogenous SARS-CoV fragments. Oral vaccination of an attenuated Salmonella typhimurium strain transformed with plasmids encoding CEA-SARS-CoV fusion gene into BALB/c mice elicited significant increases in TNF-α and IL-10 in the serum. In addition, a smaller tumor volume was observed in CT26/CEA-bearing mice who received CEA-SARS-CoV gene therapy in comparison with those administered CEA alone.

Conclusion: The administration of fusing CEA-SARS-CoV fragments may provide a promising strategy for strengthening the anti-tumor efficacy against low-immunogenic endogenous tumor antigens.

No MeSH data available.


Related in: MedlinePlus

Serum cytokine profiles of BALB/c mice orally-vaccinated with CEA-SARS-derived epitopes. Sera samples were collected for in vivo cytokine detection, including (a) TNF-α and (b) IL-10. (*, p < 0.05 in comparison with the control and the pCEA group).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3298716&req=5

Figure 2: Serum cytokine profiles of BALB/c mice orally-vaccinated with CEA-SARS-derived epitopes. Sera samples were collected for in vivo cytokine detection, including (a) TNF-α and (b) IL-10. (*, p < 0.05 in comparison with the control and the pCEA group).

Mentions: To examine the cytokine profiles of the different immunized groups quantitatively, sera samples were collected from each group 4 weeks after vaccination (i.e., 2 weeks after tumor inoculation), and cytokines representing Th1 (TNF-α,) and Th2 (IL-10) were detected by ELISA. The pCEA-SARS-CoV group revealed significantly higher TNF-α and IL-10 production than the pCEA and control groups (p < 0.05) (Figure 2)


Enhancement of anti-murine colon cancer immunity by fusion of a SARS fragment to a low-immunogenic carcinoembryonic antigen.

Lin CS, Kao SH, Chen YC, Li CH, Hsieh YT, Yang SC, Wu CJ, Lee RP, Liao KW - Biol Proced Online (2012)

Serum cytokine profiles of BALB/c mice orally-vaccinated with CEA-SARS-derived epitopes. Sera samples were collected for in vivo cytokine detection, including (a) TNF-α and (b) IL-10. (*, p < 0.05 in comparison with the control and the pCEA group).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3298716&req=5

Figure 2: Serum cytokine profiles of BALB/c mice orally-vaccinated with CEA-SARS-derived epitopes. Sera samples were collected for in vivo cytokine detection, including (a) TNF-α and (b) IL-10. (*, p < 0.05 in comparison with the control and the pCEA group).
Mentions: To examine the cytokine profiles of the different immunized groups quantitatively, sera samples were collected from each group 4 weeks after vaccination (i.e., 2 weeks after tumor inoculation), and cytokines representing Th1 (TNF-α,) and Th2 (IL-10) were detected by ELISA. The pCEA-SARS-CoV group revealed significantly higher TNF-α and IL-10 production than the pCEA and control groups (p < 0.05) (Figure 2)

Bottom Line: It is widely understood that tumor cells express tumor-associated antigens (TAAs), of which many are usually in low immunogenicity; for example, carcinoembryonic antigen (CEA) is specifically expressed on human colon cancer cells and is viewed as a low-immunogenic TAA.How to activate host immunity against specific TAAs and to suppress tumor growth therefore becomes important in cancer therapy development.Oral vaccination of an attenuated Salmonella typhimurium strain transformed with plasmids encoding CEA-SARS-CoV fusion gene into BALB/c mice elicited significant increases in TNF-α and IL-10 in the serum.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Biological Science and Technology, National Chiao-Tung University, Hsin-Chu, Taiwan. liaonms@pchome.com.tw.

ABSTRACT

Background: It is widely understood that tumor cells express tumor-associated antigens (TAAs), of which many are usually in low immunogenicity; for example, carcinoembryonic antigen (CEA) is specifically expressed on human colon cancer cells and is viewed as a low-immunogenic TAA. How to activate host immunity against specific TAAs and to suppress tumor growth therefore becomes important in cancer therapy development.

Results: To enhance the immune efficiency of CEA in mice that received, we fused a partial CEA gene with exogenous SARS-CoV fragments. Oral vaccination of an attenuated Salmonella typhimurium strain transformed with plasmids encoding CEA-SARS-CoV fusion gene into BALB/c mice elicited significant increases in TNF-α and IL-10 in the serum. In addition, a smaller tumor volume was observed in CT26/CEA-bearing mice who received CEA-SARS-CoV gene therapy in comparison with those administered CEA alone.

Conclusion: The administration of fusing CEA-SARS-CoV fragments may provide a promising strategy for strengthening the anti-tumor efficacy against low-immunogenic endogenous tumor antigens.

No MeSH data available.


Related in: MedlinePlus